Abnormal thyroid function tests were reported in up to 15% of patients treated with the PD-1 inhibitor pembrolizumab.
Debra Wood
Advertisement
Articles by Debra Wood
The oral multikinase inhibitor cabozantinib showed promise as a second- or third-line therapy in patients with advanced radioactive iodine-refractory differentiated thyroid cancer.
Advertisement
Latest Updated Articles
Second-Line Cabozantinib Effective in RAI-Refractory DTCPublished: October 21st 2015 | Updated:
Mayo Study Characterizes Pembrolizumab-Induced ThyroiditisPublished: October 23rd 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
5